Lupin Limited (LUPIN) makes its debut in Dow Jones Best-in-Class Indices 2026, highlighting its strong ESG performance and commitment to sustainability.
GPT Healthcare Limited (NSE: GPTHEALTH) reported a 24.30% y-o-y revenue growth for Q4 FY26, reaching Rs. 128.0 crore.
Strides Pharma Science Limited (STAR) reveals robust FY26 results with a 50% YoY growth in operational PAT and a 21% rise in Ex-US markets.
Glenmark Pharmaceuticals Limited (GLENMARK) launches Vancomycin Hydrochloride for Injection in USA, expanding access to quality, affordable medicines.
Valiant Laboratories Limited (VALIANTLAB) announces its board's in-principle approval to explore restructuring options for achieving synergies.
Gland Pharma Limited (NSE: GLAND) reports record revenues and profitability with 22% YoY growth in Q4 FY26 and 97% PAT growth.
Lupin Limited (LUPIN) inaugurates Atharv Ability, a state-of-the-art neuro-rehabilitation center in Delhi, expanding access to advanced care for neurological disorders.
Global Health Limited (MEDANTA) reported consolidated revenue of INR 45,089 million for FY2026, up 19.6% y-o-y, with PAT growing 15.1%.
Metropolis Healthcare Limited (METROPOLIS) reports strong Q4 & FY26 results with revenue up 32% and PAT surging 23%.
Inventurus Knowledge Solutions Limited (IKS) reports robust FY26 financial results with 20% revenue growth and a 48% surge in Profit After Tax.